ArticleFrontiers in immunology2026
Machine learning meets psoriasis: identifying key lactylation biomarkers as potential targets for diagnosis and therapies.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Psoriasis is a long-term autoimmune skin condition marked by repeated inflammation. Recent findings indicate that affected skin in psoriasis shows increased aerobic glycolysis and lactate buildup, suggesting that protein lactylation may play a role in the disease. However, biomarkers related to lactylation for diagnosing and treating psoriasis remain poorly defined. Methods: Initially, genes with altered expression in psoriasis were identified. Key gene modules from Weighted Gene Co-expression Network Analysis (WGCNA) were used to pinpoint psoriasis-associated genes. These genes were then intersected with lactylation-related genes. Random Forest and LASSO regression algorithms selected lactylation-related biomarkers. Mouse psoriasis models were created using imiquimod to validate key gene expression. The immune microenvironment in psoriasis lesions was analyzed with CIBERSORT. Regulatory networks of miRNAs(microRNAs)-genes and TFs(Transcription Factors)-genes were built using NetworkAnalyst. Potential drugs targeting these biomarkers were predicted via the DSigDB database, and their expression and distribution were visualized in single-cell sequencing data. Finally, two-sample Mendelian randomization and summary data-based Mendelian randomization were performed to investigate the causal relationship between the biomarkers and psoriasis. Results: A total of 1,623 key genes associated with psoriasis were identified through differential gene screening and WGCNA analysis. Among these, 26 were related to lactylation. Machine learning pinpointed MPHOSPH6, ENO1, MKI67, and FABP5 as lactylation-related biomarkers for psoriasis, with ROC curves confirming their strong diagnostic capabilities. RT-qPCR experiments validated their reliability, and immune infiltration analysis showed significant correlations with immune cells. Additionally, 103 drugs targeting these biomarkers were found in the DSigDB database. Mendelian randomization analysis suggested that high levels of MPHOSPH6 and ENO1 are risk factors for psoriasis. Conclusion: MPHOSPH6, ENO1, MKI67, and FABP5 are identified as lactylation-related biomarkers for psoriasis, with MPHOSPH6 and ENO1 overexpression posing as risk factors. These findings offer potential new diagnostic and therapeutic targets for the disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.